Language

Andrés Wiernik Rodríguez

Andrés Wiernik Rodríguez

Hematology
Oncology
Patient Demographics: Adult, Elderly
The information in this profile is responsability of the doctor

Make an appointment

  • Hospital Metropolitano LindoraPozos, Santa Ana, San José, Costa Rica
    300 meters north of the Catholic Church of Pozos de Santa Ana
    Thu
    03/28/24
    Fri
    03/29/24
    Sat
    03/30/24
    Sun
    03/31/24
    Mon
    04/01/24
    Tue
    04/02/24
    Wed
    04/03/24

    Searching for availability...

    Click on an hour to book an appointment or contact the clinic

Procedures (1)

General Inquiry

Medical conditions (22)

Anemia
Breast cancer
Embolism
Lung cancer
Non-Hodgkin's Lymphoma
Blood iron deficiency (sideropenia)
Bone cancer
Disseminated intravascular coagulation
Factor XII coagulation deficiency
Glucose-6-phosphate dehydrogenase (G-6-PD)
Hemoglobinuria
Hemophilia
Hodgkin's disease
Hodgkin's lymphoma
Leukemia
Low white blood cell count (leukopenia)
Lymphatic cancer
Melanoma
Mouth cancer
Multiple myeloma
Myelodysplasia
Neoplasm
Show all medical conditions

General Info

Languages

English, עברית, Español

Education

Degrees
  • Specialty in Medical Oncology. University of Minnesota - University of Minnesota Medical School. 2010 - 2013
  • Specialty in Hematology. University of Minnesota - University of Minnesota Medical School. 2010 - 2013
  • Specialty in Internal Medicine. Hennepin County Medical Center - Minnesota. 2007 - 2010
  • Specialty in Tumor Immunology. Karolinska Institutet - Cancer Center. 2006 - 2007
  • Internship - Oncology. Harvard Medical School. 2005 - 2006
  • Doctor in medicine. Universidad de Ciencias Médicas. 2000 - 2005
Fellowships
  • Medical Oncology

  • Benign and Oncologic Hematology

  • Bone Marrow Transplants

Courses
  • Controversies in Breast and Prostate Cancer Screening - Grand Rounds Lecture, Hennepin County Medical Center, Minnesota

    2017

  • Immune checkpoint modulators in Oncology and Hematology - International Summit on novel therapies and new drugs, XIII annual meeting, Plenary session, ASCO sponsored event, Queretaro, Mexico

    2017

  • Immune surveillance and Immune edting: From the lab to the clinic - International Summit on novel therapies and new drugs, XIII annual meeting, ASCO sponsored event, Queretaro, Mexico

    2017

  • T-cell engineering in Hematology - International Summit on novel therapies and new drugs, XIII annual meeting, ASCO sponsored event, Queretaro, Mexico

    2017

  • Medismart and Oncosmart: Developing a low cost private health care initiative in Costa Rica - Sanford Oncology Conference, Sioux Falls

    2017

  • Health Access and Affordable Care Delivery Systems in Latin America - Brown Bag Research Conference, University of Minnesota

    2017

  • Targeting Cancer with Cells. Grand Rounds - Veteran Affairs Medical Center (VAMC), Minneapolis

    2015

  • The magic bullet in cancer immunotherapy, Lloyd Ralston Lecture Series – Altru Health System, Grand Forks, North Dakota

    2014

  • Cancer immunotherapy in lung cancer: the future is here - Lung Cancer Symposium, Hennepin County Medical Center, Minneapolis, Minnesota

    2013

  • Cancer immunotherapy 2013: the future is here - Grand Rounds, Hennepin County Medical Center, Department of Medicine, Minneapolis, Minnesota

    2013

Trainings
  • Internship

    2006-2007 Research Fellowship: Cancer Immunology - Karolinska Cancer Center, Karolinska Institute

  • Internship

    2009 Research Internship: Cancer Immunology - University of Turin, Torino, Italy

  • Internship

    2010 Research Internship: Cancer Immunology - Peter MacCallum Cancer Center, Melbourne, Australia

Professional

Licenses
  • Physicians and Surgeons College of Costa Rica cod. MED8759Inactive

    Medic and Surgeon - Costa Rica

  • Minnesota Medical License cod. 56240Active

    United States

Affiliations
  • American Society of Hematology
  • American Society of Clinical Oncology
  • American Board of Internal Medicine
  • American Board of Internal Medicine – Hematology
  • American Board of Internal Medicine – Medical Oncology
  • American Association of Cancer Research
  • American Society for Blood and Marrow Transplantation
Awards
  • 2018 Twin Cities Rising Star Doctor - MSPMAG
  • 2016 Minnesota Best Doctors 2016 – Medical Oncology and Hematology
  • 2015 Distinguished Clinical Mentor of the year - University of Minnesota
  • 2015 Distinguished Teaching Award - University of Minnesota
  • 2012 Abstract Achievement Award, 54th ASH Annual Meeting- American Society of Hematology, Atlanta, Georgia
  • 2011 Alpha Omega Alpha-Honor Medical Society - University of Minnesota
  • 2010 Distinguished Teaching Award - Minnesota Medical Foundation
  • 2010 Best Teacher Resident Award – Internal Medicine Program, Hennepin County Medical Center
  • 2010 Best Teacher Resident Award – Transitional Residency Program, Hennepin County Medical Center
Positions
  • Staff Physician - Hennepin County Medical Center - Minneapolis, MN, USA
  • Assistant Professor of Medicine - University of Minnesota Medical Center
  • Medical Director - Cancer Center Hospital Metropolitano, Costa Rica
Publications
  • Touma W, Hoostal S, Peterson RA, Wiernik A, SantaCruz KS, Lou E. Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection. J Clin Neurosci 2017 Jul;41:75-77
  • Rosenstein BE, Ives ST, Wiernik A. A clue in JAK2: masked polycythemia vera. Am J Med. 2016 Jul 14.
  • Gleason MK, Ross JA, Warlick ED, Lund TC, Verneris MR, Wiernik A, Spellman S, Haagenson MD, Lenvik AJ, Litzow MR, Epling-Burnette PK, Blazar BR, Weiner LM, Weisdorf DJ, Vallera DA, Miller JS. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells from MDS patients against primary MDS and MDSC CD33+ targets. Blood. 2014;123(19):3016-3026.
  • Wiernik A, Foley B, Zhang B, Verneris MR, Warlick ED, Gleason MK, Ross JA, Luo X, Weisdorf DJ, Walcheck B, Vallera DA, Miller JS. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager (BiKE) and ADAM17 inhibition. Clin Cancer Res. 2013;19(14):3844-3855
  • 1.Wiernik A, Sperr WR, Weisdorf D, Valent P, Ustun C. Does high-dose cytarabine (HiDAC) cause cumulative toxicity in patients undergoing consolidation therapy for acute myeloid leukemia (AML)? Am J Hematol. 2013;88(6):533-534
  • Conway A, Wiernik A, Rawal A, Lam C, Mesa H. Occult primary medullary thyroid carcinoma presenting with pituitary and parotid metastases: case report and review of the literature. Endocr Pathol. 2012;23(2):115-122
  • Pegram HJ, Ritchie DS, Smyth MJ, Wiernik A, Prince HM, Darcy PK, Kershaw MH. Alloreactive natural killer cells in hematopoietic stem cell transplantation. Leuk Res. 2011;35(1):14-21